Introduction {#S1}
============

Leptomeningeal carcinomatosis (LC) is found in around 4% of patients with non-small cell lung cancer (NSCLC), and it is associated with a median survival of only 5 months ([@B1]). Although diffuse leptomeningeal enhancement in contrast-enhanced brain magnetic resonance imaging (MRI) is the most sensitive and non-invasive diagnostic tool for LC, false-negative, or non-specific brain MRI findings have been reported in 30% of patients ([@B2]). Herein, we report a novel brain MRI finding in four patients with NSCLC and LC, and discuss the findings of a literature review.

An Illustrative Case {#S2}
====================

A 39-year-old male smoker with diabetes mellitus was diagnosed with lung adenocarcinoma with epidermal growth factor receptor (EGFR) gene mutations in June 2011. He was treated with tumor resection and adjuvant chemotherapy (vinorelbine and cisplatin). Lung-to-lung metastasis developed in March 2012, after which he was treated with gefitinib. In July 2012, he presented with progressive dizziness, tinnitus, hearing impairment, seizures, and unsteady gait. A neurological examination revealed nystagmus, binocular diplopia, and ataxic gait. Brain MRI showed a non-enhanced band-like lesion along the anterior surface of the middle cerebellar peduncle, pons, and medulla with a high signal on fluid attenuation inversion recovery (FLAIR) imaging, and a restricted diffusion pattern on diffusion-weighted imaging (DWI) and apparent diffusion coefficient (ADC) mapping (Figure [1](#F1){ref-type="fig"}). Cerebrospinal fluid (CSF) analysis showed mild pleocytosis (white blood cell count 7/mm^3^), elevated protein (376.9 mg/dl), elevated carcinoembryonic antigen (805.9 ng/dl), and a negative oligoclonal band. CSF cytology showed malignant cells. Serum anti-Ma2 antibodies and anti-glutamic acid decarboxylase antibodies were positive.

![Serial brain magnetic resonance imaging (MRI) of case 1. Initial brain MRI **(A)** showed a high signal in diffusion-weighted imaging (DWI) at the anterior pons (arrow head) with a low signal in apparent diffusion coefficient (ADC) mapping (white arrow), hyperintensities in fluid attenuation inversion recovery (FLAIR) imaging (black arrow), and no enhancement in T1-weighted imaging with contrast (T1 C). Brain MRI 4 months later **(B)** and 7 months later **(C)** showed a thickening of the anterior pons lesion in the FLAIR imaging (black arrow), but gradual resolution of the restricted diffusion pattern in DWI (arrow head) and ADC mapping (white arrow).](fneur-08-00579-g001){#F1}

Our initial diagnosis was paraneoplastic brainstem encephalitis. Intravenous steroids and intravenous immunoglobulin were given in September 2012; however, his dizziness and ataxic gait did not improve. Under the further suspicion of LC, intrathecal chemotherapy with cytarabine and methotrexate was administered, with gefitinib being shifted to erlotinib in November 2012. Follow-up brain MRI after 3 months showed persistent hyperintensity on FLAIR imaging but regression of restricted diffusion of the anterior brainstem lesions (Figure [1](#F1){ref-type="fig"}). However, he experienced progressive general weakness in the following months, and finally died of septic shock in August 2013.

Summary of Other Cases {#S3}
======================

Three other cases with similar brain MRI findings were identified retrospectively in our hospital (Table [1](#T1){ref-type="table"}). The age of the three cases ranged from 41 to 81 years, and included two females and one male. The brief histories of these three cases are described below.

###### 

Clinical characteristics of the cases in the literature and our case series.

  Reference               Age (year)/sex                                  Cancer type                    EGFR mutation                                                      Metastasis                                           Chemotherapy agents used before the brain lesion was diagnosed   Neurological signs                                                                  CSF cytology      Paraneoplastic antibodies               Treatments for the brain lesions                                                           Prognosis
  ----------------------- ----------------------------------------------- ------------------------------ ------------------------------------------------------------------ ---------------------------------------------------- ---------------------------------------------------------------- ----------------------------------------------------------------------------------- ----------------- --------------------------------------- ------------------------------------------------------------------------------------------ ---------------------------------------------------
  Khil et al. ([@B3])     75/M                                            Lung adenocarcinoma            NA, but supposed to be positive[^c^](#tfn3){ref-type="table-fn"}   Bone                                                 Gefitinib                                                        Headache and dizziness                                                              Malignant cells   Negative antibodies in serum            NA                                                                                         Expired due to respiratory failure 1 month later
  Khil et al. ([@B3])     47/F                                            Lung adenocarcinoma            NA                                                                 Brain[^b^](#tfn2){ref-type="table-fn"}               Docetaxel and carboplatin                                        General weakness, seizure, and drowsiness                                           NA                NA                                      Whole brain radiotherapy                                                                   Hospice care
  Crombe et al. ([@B4])   56/M                                            Lung adenocarcinoma            Positive                                                           Bone, lung                                           Gefitinib                                                        Diplopia, ataxia, drowsiness, and facial hypoesthesia                               Malignant cells   Negative antibodies in serum and CSF    NA                                                                                         Expired due to respiratory failure 2 months later
  Case 1                  39/M                                            Lung adenocarcinoma            Positive, exon 19 deletion                                         Lung                                                 Vinorelbine, cisplatin, and gefitinib                            Dizziness, tinnitus, hearing impairment, seizure, nystagmus, diplopia, and ataxia   Malignant cells   Positive anti-Ma2 antibodies in serum   Intravenous steroid, intravenous immunoglobulin, intrathecal chemotherapy, and Erlotinib   Expired due to septic shock 1 year later
  Case 2                  Not be shown[^a^](#tfn1){ref-type="table-fn"}   Lung adenocarcinoma            Positive                                                           Lung, brain[^b^](#tfn2){ref-type="table-fn"}         Vinorelbine, cisplatin, docetaxel, gemcitabine, and gefitinib    Dizziness, unsteady gait, and seizure                                               NA                NA                                      Brain radiotherapy                                                                         Lost to follow-up
  Case 3                  Not be shown[^a^](#tfn1){ref-type="table-fn"}   Lung adenosquamous carcinoma   Positive, exon 21 L858R point mutation                             Lung, bone                                           No                                                               Dysphagia, dysarthria, general weakness, consciousness changes, and seizure         Negative          Negative antibodies in serum and CSF    Gefitinib, Afatinib                                                                        Expired due to respiratory failure 7 months later
  Case 4                  Not be shown[^a^](#tfn1){ref-type="table-fn"}   Lung adenocarcinoma            Positive, exon 19 deletion and codon 790 mutation                  Lung, bone, brain[^b^](#tfn2){ref-type="table-fn"}   Erlotinib, vinorelbine, pemetrexed, and gemcitabine              Dizziness, unsteady gait, and general weakness                                      NA                NA                                      Brain radiotherapy, Osimertinib                                                            Survived over 6 months

*^a^This information cannot be shown because we did not get informed consent from these patients*.

*^b^Brain parenchymal metastasis*.

*^c^The author did not mention if there was EGFR mutation, but the patient received Gefitinib*.

*CSF, cerebrospinal fluid; EGFR, epidermal growth factor receptor; NA, not available*.

The first case had lung adenocarcinoma with EGFR gene mutations and lung-to-lung metastasis. The case received tumor resection, adjuvant chemotherapy (gemcitabine, cisplatin, docetaxel, and vinorelbine), and gefitinib. Four years later, the case presented with progressive dizziness, unsteady gait, and seizures. Brain MRI showed parenchymal metastasis at the left cerebellum and a non-enhanced symmetric band-like anterior brainstem lesion with a restricted diffusion pattern (Figure [2](#F2){ref-type="fig"}). The case received brain radiotherapy for a short period but was later lost to follow-up.

![Brain magnetic resonance imaging of case 2, 3, and 4. A high signal in diffusion-weighted imaging (DWI) at the lower pons level (arrow head) and upper pons level (white arrow) with a corresponding low signal on apparent diffusion coefficient (ADC) mapping and hyperintensities on fluid attenuation inversion recovery (FLAIR) imaging (black arrow) in case 2 **(A)**, case 3 **(B)**, and case 4 **(C)**.](fneur-08-00579-g002){#F2}

The second case had progressively slurred speech, swallowing difficulties, and general weakness for 2 weeks before visiting our neurology clinic. Brain MRI showed non-enhanced symmetric band-like anterior brainstem lesions with restricted diffusion (Figure [2](#F2){ref-type="fig"}). A CSF study showed no pleocytosis but an elevated protein level (119 mg/dl). There were no malignant cells in the CSF cytology. A chest X-ray and chest computed tomography showed lung tumors, and pathology showed lung adenosquamous carcinoma with EGFR gene mutations. Lung-to-lung and bone metastases were also noted. A paraneoplastic antibody survey in serum and CSF were negative. The case received gefitinib treatment; however, the dysphagia and dysarthria progressed further. Follow-up brain MRI showed progressive anterior brainstem lesions, so the physician shifted gefitinib to afatinib for better central nervous system penetration. However, the case became comatose and died 7 months later.

The third case had lung adenocarcinoma with EGFR gene mutations and lung-to-lung and bone metastases. The case received erlotinib, vinorelbine, pemetrexed, and gemcitabine, but the lung cancer still progressed. Two years later, the case suffered from poor appetite, dizziness, general weakness, and unsteady gait. Brain MRI showed numerous enhancing nodules in the bilateral cerebellum and cerebrum, suggesting brain metastasis. The case received whole brain radiotherapy and osimertinib. Follow-up brain MRI showed the disappearance of almost all of the enhancing nodules, but also revealed newly developed restricted diffusion lesions at the anterior brainstem and bilateral corona radiata (Figure [2](#F2){ref-type="fig"}). However, the clinical condition and lung lesions were stable. The case was kept on osimertinib treatment and was still alive at the time this manuscript was written.

Literature Review {#S4}
=================

We reviewed the literature and identified three more cases with similar brain MRI findings ([@B3], [@B4]). The clinical characteristics of the seven cases are summarized in Table [1](#T1){ref-type="table"}. There were four males and three females, with an average age of 57 years (range 39--81 years). All of the cases had NSCLC, with six having adenocarcinoma and one adenosquamous carcinoma. All had bone, lung, or brain parenchymal metastasis. Five cases had confirmed EGFR gene mutations. The interval between the diagnosis of lung cancer and discovery of the brainstem lesions ranged from 3 months to 4 years. In one patient (case 3), anterior brainstem lesions led to the diagnosis of lung cancer. Five cases had used a thyroxine kinase inhibitor (TKI) before discovery of the brainstem lesions. The associated neurological symptoms included dizziness, unsteady gait, seizures, diplopia, drowsiness, headache, general weakness, facial hypoesthesia, tinnitus, hearing impairment, dysarthria, and dysphagia. Three cases had malignant cells in CSF, and three other cases had brain parenchymal metastasis. One case had positive anti-Ma2 antibodies in their serum. The brain lesions were treated with radiotherapy in three cases, intrathecal chemotherapy in one case, and TKIs in three cases. The case with positive anti-Ma2 antibodies was treated with intravenous steroids and intravenous immunoglobulin; however, the response was poor. The prognosis seemed to be poor in most of the cases, with survival of less than 1 year after identification of the brain lesions.

Discussion {#S5}
==========

The most prominent feature of the anterior brainstem lesions on brain MRI in these patients was a high signal on DWI and FLAIR imaging with a corresponding low signal on ADC mapping. This can be described as a "restricted diffusion" pattern, which is thought to represent cytotoxic edema ([@B5]). Restricted diffusion develops most commonly in acute ischemic stroke and sometimes in prolonged status epilepticus, mitochondrial disease, or prion disease ([@B5]). However, these etiologies were very unlikely in our patients given their clinical presentations and CSF findings. Restricted diffusion has also been reported in high cellular brain tumors such as lymphoma, high-grade glioma, central necrosis of brain abscesses, and some metastases ([@B6]). However, these brain tumors often have strong contrast enhancement on brain MRI ([@B6]), which was not found in our cases. The CSF cytology and cultures in our cases also did not favor these etiologies.

Considering that all of the patients had lung cancer, other etiologies such as LC, paraneoplastic neurological syndrome (PNS) or chemotherapy-related toxic encephalopathy may explain the brain lesions. Chemotherapy-related toxic encephalopathy was unlikely because different chemotherapy agents or TKIs were given in six cases, and one case was treatment-naive. PNS was also less likely because the brainstem findings did not fit any known PNS. Moreover, only one case had positive anti-Ma2 antibodies, and this case exhibited a poor response to intravenous steroid and intravenous immunoglobulin treatment. Considering that three cases had malignant cells in their CSF and another three cases had brain parenchymal metastasis, LC was the most likely etiology.

The most common brain MRI finding of LC is diffuse leptomeningeal enhancement ([@B2]). However, the brain MRI lesions in our patients were non-enhanced. In fact, restricted diffusion has rarely been reported as an imaging finding for LC. Hu et al. reported a 77-year-old female with lung adenocarcinoma who presented with rapidly progressive consciousness changes ([@B7]). Her brain MRI showed restricted diffusion along the surface of the bilateral occipital cortex, and since CSF cytology showed malignant cells, LC was suspected. Ayzenberg et al. also reported a 77-year-old male with lung adenocarcinoma who presented with consciousness changes ([@B8]). His brain MRI showed restricted diffusion over bilateral cortical and subcortical areas. He fell into a coma and died 5 days later. A postmortem neuropathological examination was consistent with LC, showing extensive tumor cell infiltration as well as microinfarctions due to intracapillary infiltration of tumor cells *via* Virchow-Robin spaces. We speculate that the anterior brainstem restricted diffusion in our case series may have been caused by malignant cells concentrating in the CSF cistern around the brainstem and then infiltrating into the circumferential perforating arteries along the anterior brainstem surface, thereby resulting in microinfarctions.

Most cases in our series had NSCLC with EGFR mutations, for which survival has been shown to be longer if treated with TKIs; however, the central nervous system was a frequent site of recurrence in these patients ([@B9]). The reported median survival after a diagnosis of LC is only a few months ([@B1], [@B2]). In this study, three cases survived for only a few months, two cases had an unknown survival length, one case who received TKIs and intrathecal chemotherapy survived for 1 year, and the other case who received TKIs and brain radiotherapy had survived for more than 6 months when this manuscript was written. Several studies have reported that TKIs with better blood--brain barrier penetration, a higher dosage of TKIs, intrathecal chemotherapy, whole or focal brain radiotherapy, or a combination of multiple treatment strategies may improve the outcome of patients with LC ([@B1], [@B10]).

In conclusion, we reported a novel brain MRI finding with anterior brainstem restricted diffusion in patients with NSCLC. We believe that this is a new imaging finding of LC, and that it may be caused by high cellularity of the tumor cells on the brainstem or microinfarctions due to intracapillary tumor cell infiltration. Because brain MRI is an easily accessible and non-invasive diagnostic tool for LC, the identification of this unique imaging finding could be helpful in diagnosing LC. More case series are warranted and may provide further information about the risk factors and prognosis of patients with this imaging finding. Further studies with a larger number of cases and biopsy or autopsy findings may be able to elucidate the pathological features associated with this imaging finding and support our hypothesis.
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